

15 December 2011 EMA/802336/2011 Press Office

Overview of invented names reviewed in November 2011 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 12-15 December 2011

	NRG meeting 25 Jan 2011		NRG meeting 22 March 2011		NRG meeting 24 May 2011		NRG meeting 28 June 2011		NRG meeting 22 Sept 2011		NRG meeting 17 Nov 2011		2011	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejecte	Accepted	Rejecte	Accepted	Rejected
Proposed invented names	34	68	56	50	59	41	56	55	49	41	93	50	343	305
Justification for retention of invented name *	0	2	4	6	2	4	4	0	1	2	5	9	16	23

*In case of objections to the proposed invented name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMEA website.

	NRG meeting 25 Jan 2011		NRG meeting 22 March 2011		NRG meeting 24 May 2011		NRG meeting 28 June 2011		NRG meeting 22 Sept 2011		NRG meeting 17 Nov 2011		2011	
Objections	Accepted	Rejected	Accepted	Rejecte	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Total number of objections raised	155	90	102	91	94	63	95	41	75	67	102	112	623	464
Criterion - Safety concerns														
Similarity with other Invented name	125	73	82	74	48	53	87	26	68	51	91	84	433	311
Conveys misleading therapeutic/pharmaceutical connotations	2	3	0	1	1	0	1	1	1	3	0	3	5	11
Misleading with respect to composition	3	1	5	5	6	0	0	0	0	2	7	7	21	15
Criterion - INN concerns														
Similarity with INN	8	6	5	2	4	1	3	0	2	1	0	3	22	13
Inclusion of INN stem	5	3	3	2	3	0	1	3	0	8	1	4	13	20

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom **Telephone** +44 (0)20 7418 8427 **Facsimile** +44 (0)20 7418 8409 **E-mail** press@ema.europa.eu **Website** www.ema.europa.eu



An agency of the European Union

 \odot European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged.

	NRG meeting 25 Jan 2011		NRG meeting 22 March 2011		NRG meeting 24 May 2011		NRG meeting 28 June 2011		NRG meeting 22 Sept 2011		NRG meeting 17 Nov 2011		2011	
Criterion - Other public health concerns														
Unacceptable qualifiers	1	0	3	2	2	0	0	1	0	0	0	1	6	4
Conveys a promotional message	1	0	2	5	0	8	3	1	3	2	1	4	10	20
Appears offensive or has a bad connotation	1	0	2	0	1	0	0	0	0	1	5	0	9	1
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0	0	0	2	1	0	0	1	0	0	0	3	1
Similarity between name of prodrug and related	0	0	0	0	0	0	0	0	0	0	0	0	0	0

active substance

See Guideline on the Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure (CPMP/328/98 Rev. 5) for detailed explanations of criteria used.